Nanobiotix Stock Rebounds Nearly 2%, But Remains Below Its 50-Day Moving Average
The French biotech regains some color midday, after several sessions of decline. The stock is moving into positive territory in a Parisian market that is also trending upwards. The rebound occurs as the stock price approached its medium-term moving average.
Technical Rebound at the 50-Day Moving Average After a Month of Decline
Nanobiotix stock gains 1.76% at €31.28 during the session, within an SBF 120 that is up 0.8%. The stock ranks in the middle of the broad index, away from today's leaders.
The movement comes after a June that started in the red, with a decline of 15.23% over thirty days. The price is just below its 50-day moving average (€31.71, gap -1.36%), a level it attempts to reclaim during the session.
Higher up, the 20-day moving average at €36.21 remains distant, more than 13% above the current price. The RSI at 42 indicates a still recovering momentum, without a clear reversal signal.
A Consolidation That Doesn't Erase an Extraordinary Annual Rally
Despite the recent weeks' decline, the twelve-month performance remains spectacular, at over 650%. The price still hovers around 44% above its 200-day moving average (€21.73), reflecting the magnitude of the bullish journey that began last year.
The fundamental context remains supportive on the clinical front. During the first quarter of 2026 release (June 2, 2026), the company highlighted the progress of studies on JNJ-1900 (NBTXR3) and the strengthening of the Nanoprimer platform, while noting the limited progress of the current standard of care in inoperable lung cancer as one of the identified risks.
Cash reserves were bolstered in early June through a capital increase of €86.1 million, bringing liquidity to €42.1 million as of March 31, 2026. The next technical milestone to watch remains the reconquest of the 50-day moving average at €31.71.
